

## BSW Formulary Update – Following APC June 2021 meeting

### New and Updated Prescribing Guidelines/Shared care Guideline

- **Updated – [BSW&AWP Shared Care Guideline for the Treatment of Alzheimer's Disease](#)**. Update adds contact details from the 3 acute Trusts into an existing SCA that previously just included the commissioned AWP memory clinic. Additionally, references to galantamine **tablets** have been removed; this formulation is discontinued but [galantamine modified release capsules](#) still available.

### New additions to the BSWformulary

- [Labinic Probiotic Drops](#) For use on an inpatient basis in line with the South West neonatal guidance. **RED TLS**
- [Plasma-Lyte 148 and Plasmalyte 148 with 5% glucose](#) For paediatric use; brings fluid regimens in line with neighbouring specialist paediatric centres (Bristol/Oxford). **RED TLS**
- [Lenzetto 1.53 mg/spray estradiol transdermal spray](#)  
Lenzetto<sup>®</sup> is an additional topical oestrogen HRT option considered second/third line after existing formulary choices of oestrogen patches/gels and useful for patients with allergies to patches. **GREEN TLS** *Note: BSW HRT pathway currently being updated*
- [Alirocumab 300mg/2mL pre filled pen](#)  
New strength added to existing formulary entry.
- [Non-hormonal vaginal lubricants/moisturisers \(e.g. Sylk, Replens\)](#)  
These are available OTC and online. The APC agreed patients should be directed to self-purchase in most instances due to a limited prescribing budget.

### Changes to Formulary

- [Estradiol 10microgram vaginal tablets \(cost-saving switch from Vagifem<sup>®</sup> to Vagirux<sup>®</sup>\)](#). The APC approve this cost-saving switch having confirmed that Vagirux<sup>®</sup> is equivalent to Vagifem, reliably in stock and has the benefit of less plastic waste. The switch will be driven through BSWCCG Meds Op team 'Prescribe Well Spend Less' work stream and GP prescribing messages.
- [Calcipotriol 50micrograms/g with Betamethasone 0.05% \(cost saving switch from Dovobet<sup>®</sup> to Dalonev<sup>®</sup>\)](#). The APC approve this cost-saving switch in view of the available rebate for Dalonev<sup>®</sup> ointment. The switch will be driven through BSWCCG Meds Op team 'Prescribe Well Spend Less' work stream and GP prescribing messages.
- [Hydrocortisone 3.35mg/ml eye drops 0.4ml unit dose \(Softacort<sup>®</sup>\)](#)  
Changed from RED to **AMBER TLS** to bring in line with other steroid eyedrops on BSWformulary e.g. Maxidex<sup>®</sup> and FML<sup>®</sup>. Softacort<sup>®</sup> is slightly more expensive but may be preferred due to potency, a favourable safety profile and preservative-free formulation.

Prescribers should be aware Softacort® is licensed for a max. 14 days but is sometimes recommended by ophthalmology for longer durations.

### **TLS Aligned for BSW**

- [Ethinylestradiol tablets](#) aligned with **RED TLS**
- [Eslicarbazepine tablets](#) (adjunctive therapy in adolescents and adults, where other antiepileptic treatments have been ineffective or not tolerated) aligned with **AMBER TLS**. The original BCAP SCA has been retired; further information on TLS for antiepileptics within BSWformulary found [here](#)

### **Other BSWformulary website updates**

- Pathways for the use of NICE approved High Cost biologic drugs in **atopic dermatitis** and in **migraine** have been added here <https://prescribing.bswccg.nhs.uk/blueteg>

### **What the BSW CCG formulary team are currently working on**

- Working to improve the understanding of the definition of the Traffic Light System and initiation of shared care prescribing, to improve engagement and adherence to the BSWformulary across primary and secondary care.
- Reviewing formulary position of Cox-2 inhibitors.
- Updating COPD guidance.
- Reviewing formulary application for Ferric maltol (Ferracru) and proposed pathway for its use.
- Working with AWP on an oral antipsychotic SCA.
- Reviewing the national SCA consultations by RMOC.
- Updating the HRT pathway and reviewing policies on Testosterone in HRT and on use of CGM.
- Updating the BSW primary care antibiotic guidance in line with NICE updates and reviewing TLS and primary care prescribing of rifampicin.

*The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email [bswccg.formulary@nhs.net](mailto:bswccg.formulary@nhs.net)*